Aeglea BioTherapeutics Inc (AGLE)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
David G. Lowe
Employees:
61
901 S. MOPAC EXPRESSWAY, STE. 250, BARTON OAKS PLAZA ONE, AUSTIN, TX 78746
(512) 942-2935

Aeglea Biotherapeutics, Inc. operates as a biopharmaceutical company, which engages in developing engineered human enzymes for the treatment of inborn errors of metaboli® and cancer. It develops AEB1102, an amino acid for the degradation of arginine in the circulation, as well as for the treatment of hyperargininemia and cancer; and AEB3103, an engineered and PEGylated human cysteine/cystine degrading enzyme that increases oxidative stress through glutathione depletion for treatment of hematologic and solid malignancies; AEB2109, an engineered human enzyme that degrades methionine for the treatment of solid tumors; and AEB4104, an engineered human enzyme that degrades homocysteine in the circulation for the treatment of inborn error of metaboli® homocystinuria. The company was founded in December 13, by by George Georgiou and David G. Lowe and is headquartered in Austin, TX.

Data derived from most recent annual or quarterly report
Market Cap 294.387 Million Shares Outstanding49.065 Million Avg 30-day Volume 171.518 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.29
Price to Revenue24.9335 Debt to Equity0.0 EBITDA-64.031 Million
Price to Book Value2.8691 Operating Margin-480.52720000000005 Enterprise Value212.911 Million
Current Ratio6.522 EPS Growth0.592 Quick Ratio6.24
1 Yr BETA 0.6244 52-week High/Low 9.78 / 5.82 Profit Margin-480.3957
Operating Cash Flow Growth30.1478 Altman Z-Score4.004 Free Cash Flow to Firm -41.987 Million
View SEC Filings from AGLE instead.

View recent insider trading info

Funds Holding AGLE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AGLE BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SMITH HUNTER C

  • Director
60,000 2021-11-12 2

ALSPAUGH JONATHAN CHIEF FINANCIAL OFFICER

  • Officer
40,372 2021-08-16 3

SOUZA MARCIO

  • Director
60,000 2021-06-18 2

BAKER BROS. ADVISORS LP

667, L.P.

BAKER BROS. ADVISORS (GP) LLC

BAKER BROTHERS LIFE SCIENCES LP

BAKER FELIX

BAKER JULIAN

  • Director
40,000 2021-06-08 3

LAWLIS V BRYAN

  • Director
40,000 2021-06-08 1

MAGOVCEVIC-LIEBISCH IVANA

  • Director
40,000 2021-06-08 1

MAHATME SANDESH

  • Director
40,000 2021-06-08 1

COX RUSSELL J.

  • Director
40,000 2021-06-08 1

LAWTON ALISON FRANCES

  • Director
40,000 2021-06-08 3

SHANAFELT ARMEN

  • Director
40,000 2021-06-08 1

BROWNSTEIN SARA

  • Director
0 2021-02-23 1

QUINN ANTHONY G. PRESIDENT & CEO

  • Officer
  • Director
0 2021-02-17 1

SLOAN LESLIE CHIEF OPERATING OFFICER

  • Officer
0 2021-02-17 1

HANLEY JR. MICHAEL CONICK CHIEF COMMERCIAL OFFICER

  • Officer
0 2021-02-17 1

WEBER STEVEN VP, CONTROLLER&PRINC ACCTG OFF

  • Officer
0 2021-02-17 2

BRUHN SUZANNE LOUISE

  • Director
0 2020-06-08 0

YORK CHARLES N II CHIEF FINANCIAL OFFICER AND VP

  • Officer
0 2020-02-14 0

RAO MADDURI RAVIN CHIEF MEDICAL OFFICER

  • Officer
0 2020-02-14 0

SCHUCHART AARON CHIEF BUSINESS OFFICER

  • Officer
0 2019-02-28 0

WOOLDRIDGE JAMES CHIEF MEDICAL OFFICER

  • Officer
0 2019-02-28 0

GEORGIOU GEORGE

  • Director
175,861 2018-08-13 0

NOVARTIS BIOVENTURES LTD

NOVARTIS AG

2,175,314 2018-05-11 0

TYLER JOSEPH E VP, MANUFACTURING

  • Officer
0 2017-08-22 0

ROWLINSON SCOTT W VP, RESEARCH

  • Officer
0 2017-08-22 0

LOWE DAVID GEORGE CEO AND PRESIDENT

  • Officer
  • Director
0 2017-03-20 0

HEBEL HENRY VP, PRODUCT DEVELOPMENT

  • Officer
0 2017-03-20 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP V LLC

ISALY SAMUEL D

  • 10% Owner
1,469,524 2017-02-16 0

ROJAS-CARO SANDRA CHIEF MEDICAL OFFICER

  • Officer
0 2016-05-17 0

LILLY ELI & CO

  • 10% Owner
2,568,543 2016-04-12 0

LILLY ELI & CO

LILLY VENTURES FUND I LLC

SHANAFELT ARMEN

  • 10% Owner
2,068,543 2016-04-12 0

LILLY VENTURES FUND I LLC

SHANAFELT ARMEN

TORRES S. EDWARD

  • Director
  • 10% Owner
57,619 2016-04-06 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

SMITH HUNTER C - Director

2021-11-16 16:34:18 -0500 2021-11-12 A 60,000 a 60,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 22:15:03 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 21:45:03 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 21:15:04 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 20:45:03 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 20:15:03 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 19:45:03 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 19:15:04 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 18:45:04 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 18:15:03 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 17:45:03 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 17:15:03 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 16:45:03 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 16:15:04 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 15:45:03 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 15:15:03 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 14:45:03 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 14:15:05 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 13:45:03 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 13:15:03 UTC -0.18 0.25 600000
AEGLEA BIOTHERAPEUTICS INC AGLE 2021-12-03 12:45:03 UTC -0.18 0.25 600000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund AGLE -200.0 shares, $-1590.0 2021-09-30 N-PORT

Elevate your investments